Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0021218067
Fri, 28.07.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LREvolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the
year
Board of Directors proposes the following to the shareholders:
Increase of the conditional capital for the purpose of Nice & Green financing
Increase in the upper limit of [ … ]
Mon, 26.06.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Reinach, 26 June 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and its financing partner Nice & [ … ]
Mon, 26.06.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Reinach, 26 June 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and its financing partner Nice & [ … ]
Wed, 14.06.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Reinach, 14 June 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, is in discussions with its financing partner Nice & [ … ]
Wed, 14.06.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Reinach, 14 June 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, is in discussions with its financing partner Nice & [ … ]
Fri, 05.05.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Reinach, 5 May 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, has reached a major milesto [ … ]
Fri, 05.05.2023
Evolva Holding SA
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Reinach, 5 May 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, has reached a major milesto [ … ]
Fri, 24.03.2023
Evolva Holding SA
Ad Hoc Announcement (PDF)
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Board of Directors proposes, among others, the following to the shareholders:
Reverse stock split of 250:1, followed by a reduction of the nominal value of the shares to CHF 1.00
Introduction of a capital band of up to 20% of current share capital to give the B [ … ]
Fri, 24.03.2023
Evolva Holding SA
Ad Hoc Announcement (PDF)
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Board of Directors proposes, among others, the following to the shareholders:
Reverse stock split of 250:1, followed by a reduction of the nominal value of the shares to CHF 1.00
Introduction of a capital band of up to 20% of current share capital to give the B [ … ]
Thu, 09.03.2023
Evolva Holding SA
Ad Hoc Announcement (PDF)
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Reinach, 9 March 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, delivered a strong performance during 2022, fully meeting its targets. Total revenue increased by 57% (prior year +40%) to CHF 15.5 million, while produ [ … ]